A massive lawsuit filed by 44 states accuses 20 major drug makers of colluding to inflate prices on more than 100 generic drugs, including HIV, cancer, and depression treatments. If these allegations are true, then this isn't just a violation of antitrust law. It's a betrayal of the policies that created and defended the entire generic drug industry.
Patients who try to stay within their insurers' networks can be hit with surprise bills when they unknowingly receive care from out-of-network physicians. How much should a physician be paid for providing a service that is critical but rendered without the patient's ready ability to choose an in-network provider?
Efforts to encourage patient price shopping through access to price transparency tools have met with limited success. However, combining these tools with reference pricing simplifies decisionmaking by steering patients to low-priced providers and giving them a financial incentive to comply with the nudge.
The international impact of pharmaceutical pricing changes in the United Kingdom is likely to be minimal or indirect. This is due largely to the diverse ways that various other countries implement international price comparisons.
Finds a negative association between nonprice competition and quality of care in managed care plans in the New York SCHIP market. Pricing policy is likely a constraint on quality production, though it may not be interpreted as a causal relationship.
This article suggests that in a market such as California, where HMOs and PPOs have gained widespread acceptance and excess hospital capacity exists, competitive market conditions can be leveraged to negotiate lower prices with health care providers.